Vir Biotechnology integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. The company is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Vir's scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academic research. Vir's initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquired infections.
Select investors ARCH Venture Partners, Alta Partners, Altitude Life Science Ventures, Bill & Melinda Gates Foundation, Temasek Holdings, Baillie Gifford, Alaska Permanent Fund, SoftBank Vision Fund
Last update: May 10, 2018
Disclaimer: We can not guarantee that the information on this page is 100% correct. more